Stefan Scheidl

Company: Roche

Job title: Franchise Head, Disease Area Ophthalmology, Global Medical Affairs

Seminars:

Panel Discussion: Future Directions for Anti-VEGF Therapies 12:10 pm

Increasing patient response rates, not just prolonging treatment duration New therapy formats (bispecifics) – how does dual-specificity open up a wide range of therapeutic applications for these multifactorial diseases? Combinatorial approaches – approaches that could potentially be used on patients currently refractory or not optimally treated with anti-VEGF-A therapy aloneRead more

day: Day One

Dual Targeting: Faricimab – A Bispecific Antibody Approach 11:30 am

Faricimab is the first innovation since over 15 years of antiVEGF monotherapy that adds a new MoA (Ang2) to the management of patients suffering from retinal vascular diseases such as nAMD and DME Pre-clinical data provides a strong rationale that targeting Ang2 increases vascular stability and reduces inflammation Phase 3 clinical data in both nAMD…Read more

day: Day One